I think it would have been nice in increasing the company profile but redirecting supply to what is a TEMPORARY measure is fraught with risks. The US diary industry is powerful. This stock is undervalued all that is needed is just an ok August report. Anything better is great news.
Ann: Deferral of FDA consideration of enforcement discretion, page-90
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$7.93 |
Change
0.130(1.67%) |
Mkt cap ! $5.741B | |||
| Open | High | Low | Value | Volume |
| $7.87 | $7.99 | $7.71 | $17.74M | 2.261M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 111 | $7.93 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $7.96 | 3799 | 2 |
View Market Depth
| Last trade - 16.13pm 27/06/2025 (20 minute delay) ? |
| A2M (ASX) Chart |